Gilder Gagnon Howe & Co Has Decreased Nxstage Med Com (NXTM) Holding; Hawaiian Telcom Holdco (HCOM) Sentiment Is 1.29

June 20, 2017 - By Adrian Mccoy

Gilder Gagnon Howe & Co Llc decreased Nxstage Med Inc Com (NXTM) stake by 2.39% reported in 2016Q4 SEC filing. Gilder Gagnon Howe & Co Llc sold 140,948 shares as Nxstage Med Inc Com (NXTM)’s stock declined 27.12%. The Gilder Gagnon Howe & Co Llc holds 5.75M shares with $150.70M value, down from 5.89M last quarter. Nxstage Med Inc Com now has $1.54 billion valuation. It closed at $23.39 lastly. It is down 21.18% since June 20, 2016 and is uptrending. It has outperformed by 4.48% the S&P500.

Hawaiian Telcom Holdco, Inc. is a provider of communications services and products in Hawaii. The company has market cap of $291.06 million. The Firm operates through two business divisions: Telecommunications and Data Center Colocation. It currently has negative earnings. The Telecommunications segment provides local telephone service, including voice and data transport, custom calling features, network access, directory assistance and private lines.

Black Diamond Capital Management L.L.C. holds 83.2% of its portfolio in Hawaiian Telcom HoldCo Inc for 2.65 million shares. Wynnefield Capital Inc owns 482,268 shares or 4.31% of their US portfolio. Moreover, Private Management Group Inc has 0.78% invested in the company for 556,419 shares. The Illinois-based North Star Investment Management Corp. has invested 0.33% in the stock. Paloma Partners Management Co, a Connecticut-based fund reported 274,128 shares.

It closed at $25.55 lastly. It is down 17.14% since June 20, 2016 and is uptrending. It has outperformed by 0.44% the S&P500.

Among 6 analysts covering NxStage Medical (NASDAQ:NXTM), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. NxStage Medical had 7 analyst reports since November 4, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, December 18 by BTIG Research. The firm earned “Outperform” rating on Tuesday, June 28 by Northland Capital. On Thursday, March 31 the stock rating was reinitiated by Piper Jaffray with “Overweight”. Sterne Agee CRT initiated the stock with “Buy” rating in Friday, December 11 report. Canaccord Genuity maintained NxStage Medical, Inc. (NASDAQ:NXTM) rating on Tuesday, August 2. Canaccord Genuity has “Buy” rating and $26 target.

Investors sentiment decreased to 0.85 in 2016 Q4. Its down 0.35, from 1.2 in 2016Q3. It turned negative, as 15 investors sold NXTM shares while 67 reduced holdings. 31 funds opened positions while 39 raised stakes. 59.80 million shares or 3.37% less from 61.88 million shares in 2016Q3 were reported. Ameriprise Fincl Inc has invested 0% in NxStage Medical, Inc. (NASDAQ:NXTM). Lpl Finance Limited Co has 0% invested in NxStage Medical, Inc. (NASDAQ:NXTM). Blackrock Gru Ltd holds 78,879 shares. Group Inc One Trading Lp reported 0% in NxStage Medical, Inc. (NASDAQ:NXTM). Amalgamated Bank & Trust invested in 7,809 shares or 0.01% of the stock. Airain Limited has invested 0.05% in NxStage Medical, Inc. (NASDAQ:NXTM). Nicholas Invest Prns LP accumulated 105,287 shares or 0.21% of the stock. Rhumbline Advisers reported 0% in NxStage Medical, Inc. (NASDAQ:NXTM). 60,594 were accumulated by Credit Suisse Ag. Essex Ltd Com has 0.29% invested in NxStage Medical, Inc. (NASDAQ:NXTM). Whitnell & Commerce holds 500 shares. Creative Planning has invested 0% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM). Pura Vida Invs Limited Liability Company has 2.47% invested in NxStage Medical, Inc. (NASDAQ:NXTM). Perceptive Advsr Ltd Liability Com reported 1.93 million shares. Chicago Equity Ltd Liability Com has invested 0.06% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM).